BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 15753966)

  • 21. Generation of B-cell chronic lymphocytic leukemia (B-CLL)-reactive T-cell lines and clones from HLA class I-matched donors using modified B-CLL cells as stimulators: implications for adoptive immunotherapy.
    Hoogendoorn M; Wolbers JO; Smit WM; Schaafsma MR; Barge RM; Willemze R; Falkenburg JH
    Leukemia; 2004 Jul; 18(7):1278-87. PubMed ID: 15116118
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Surface-Engineering of Red Blood Cells as Artificial Antigen Presenting Cells Promising for Cancer Immunotherapy.
    Sun X; Han X; Xu L; Gao M; Xu J; Yang R; Liu Z
    Small; 2017 Oct; 13(40):. PubMed ID: 28861943
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Robust expansion of viral antigen-specific CD4+ and CD8+ T cells for adoptive T cell therapy using gene-modified activated T cells as antigen presenting cells.
    Melenhorst JJ; Solomon SR; Shenoy A; Hensel NF; McCoy JP; Keyvanfar K; Barrett AJ
    J Immunother; 2006; 29(4):436-43; discussion 365-6. PubMed ID: 16799339
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epstein-Barr virus-transformed B-cells as efficient antigen presenting cells to propagate Aspergillus-specific cytotoxic T-lymphocytes.
    Ramadan G
    Egypt J Immunol; 2008; 15(1):145-57. PubMed ID: 20306679
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dissociation of its opposing immunologic effects is critical for the optimization of antitumor CD8+ T-cell responses induced by interleukin 21.
    Ansén S; Butler MO; Berezovskaya A; Murray AP; Stevenson K; Nadler LM; Hirano N
    Clin Cancer Res; 2008 Oct; 14(19):6125-36. PubMed ID: 18829491
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro expansion of polyclonal T-cell subsets for adoptive immunotherapy by recombinant modified vaccinia Ankara.
    La Rosa C; Wang Z; Lacey SF; Lalimarmo MM; Krishnan A; Longmate J; Diamond DJ
    Exp Hematol; 2006 Apr; 34(4):497-507. PubMed ID: 16569596
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells.
    Zappasodi R; Di Nicola M; Carlo-Stella C; Mortarini R; Molla A; Vegetti C; Albani S; Anichini A; Gianni AM
    Haematologica; 2008 Oct; 93(10):1523-34. PubMed ID: 18728033
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adoptive therapy using antigen-specific T-cell clones.
    Yee C
    Cancer J; 2010; 16(4):367-73. PubMed ID: 20693849
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ex vivo expansion of dendritic-cell-activated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: potential for adoptive T cell immunotherapy.
    Chen HW; Liao CH; Ying C; Chang CJ; Lin CM
    Clin Immunol; 2006 Apr; 119(1):21-31. PubMed ID: 16406844
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary allogeneic T-cell responses against mantle cell lymphoma antigen-presenting cells for adoptive immunotherapy after stem cell transplantation.
    Hoogendoorn M; Olde Wolbers J; Smit WM; Schaafsma MR; Jedema I; Barge RM; Willemze R; Falkenburg JH
    Clin Cancer Res; 2005 Jul; 11(14):5310-8. PubMed ID: 16033850
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Artificial antigen-presenting cells expressing AFP(158-166) peptide and interleukin-15 activate AFP-specific cytotoxic T lymphocytes.
    Sun L; Guo H; Jiang R; Lu L; Liu T; Zhang Z; He X
    Oncotarget; 2016 Apr; 7(14):17579-90. PubMed ID: 27007051
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression.
    Huang H; Li F; Gordon JR; Xiang J
    Cancer Res; 2002 Apr; 62(7):2043-51. PubMed ID: 11929823
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Artificial antigen-presenting cells for use in adoptive immunotherapy.
    Turtle CJ; Riddell SR
    Cancer J; 2010; 16(4):374-81. PubMed ID: 20693850
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adoptive T-cell therapy of cancer.
    Yee C
    Hematol Oncol Clin North Am; 2006 Jun; 20(3):711-33. PubMed ID: 16762731
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adoptive T-cell immunotherapy of cancer.
    Li Q; Chang AE
    Cytokines Cell Mol Ther; 1999 Jun; 5(2):105-17. PubMed ID: 10515683
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of autologous cytotoxic CD4+ T clones in a human model of B-cell non-Hodgkin follicular lymphoma.
    Mi JQ; Manches O; Wang J; Perron P; Weisbuch S; Marche PN; Renversez JC; Bensa JC; Sotto JJ; Cahn JY; Leroux D; Bonnefoix T
    Br J Haematol; 2006 Nov; 135(3):324-35. PubMed ID: 16984392
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.
    Wang Y; Aïssi-Rothe L; Virion JM; De Carvalho Bittencourt M; Ulas N; Audonnet S; Salmon A; Clement L; Venard V; Jeulin H; Stoltz JF; Decot V; Bensoussan D
    Cytotherapy; 2014 Jan; 16(1):122-34. PubMed ID: 24094498
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Toward development and production of human T cells in swine for potential use in adoptive T cell immunotherapy.
    Ogle BM; Knudsen BE; Nishitai R; Ogata K; Platt JL
    Tissue Eng Part A; 2009 May; 15(5):1031-40. PubMed ID: 18826341
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
    Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
    Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preparation of fully activated dendritic cells capable of priming tumor-specific cytotoxic T lymphocytes in patients with metastatic cancer using penicillin-killed streptococcus pyogenes (OK432) and anti-CD40 antibody.
    Kontani K; Teramoto K; Ozaki Y; Sawai S; Tezuka N; Ishida H; Kajino K; Fujino S; Yamauchi A; Taguchi O; Kannagi R; Yokomise H; Ogasawara K
    Oncol Rep; 2007 Apr; 17(4):895-902. PubMed ID: 17342333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.